Bovine Tuberculosis Diagnosis Market to Grow with a CAGR of 5.27% through 2030
The recognition of the significant economic, public
health, and animal welfare consequences associated with bTB. is expected to
drive the Global Bovine Tuberculosis Diagnosis Market growth in the forecast
period, 2026-2030.
According to TechSci Research report, “Bovine
Tuberculosis Diagnosis Market – Global Industry Size, Share,
Trends, Competition Forecast & Opportunities, 2030F”, the Global Bovine
Tuberculosis Diagnosis Market stood at USD 782.12
million in 2024 and is expected to reach USD 1066.97 Million by 2030
with a CAGR of 5.27% during the forecast period. This can be attributed to the globalization of trade. The globalization of
livestock trade has amplified concerns about disease transmission across
borders. To facilitate international trade while safeguarding against bTB,
standardized and reliable diagnostic tools are increasingly in demand. This
trend reinforces the need for a robust global bTB diagnosis market.
Genomic epidemiology, which involves
sequencing the genomes of bTB strains, is gaining importance. This approach
allows for tracing the source of infection and understanding the transmission
dynamics of the disease. Genomic data can inform more targeted control
strategies.
The growth of the market is driven by several key
factors. These include the increasing cattle population, a growing demand for
animal products, heightened concerns regarding zoonotic diseases, strategic
initiatives undertaken by major companies, and supportive regulations and
government programs. As an example, the United States Department of
Agriculture's (USDA) Animal and Plant Health Inspection Service (APHIS)
initiated the National Tuberculosis Eradication Program in 1917 to eradicate
bovine TB in the U.S. This program involves regular and systematic testing of
cattle nationwide as part of a comprehensive surveillance program, among other
measures, and is expected to contribute to the market's expansion.
However, the COVID-19 pandemic had a negative impact
on the market, particularly in 2020. This decline can be attributed to the
closure and limited access to veterinary services due to lockdowns. Bovine TB
eradication programs in various countries faced significant challenges in
conducting diagnosis procedures during the pandemic. For instance, the Minister
for Environment, Energy, and Rural Affairs (MEERA) in the U.K. reported in
November 2021 that new eradication programs and related activities had been postponed
and delayed due to the sudden public health crisis, creating operational
obstacles.
Nevertheless, government agencies and key players took
various measures to continue their eradication programs during the pandemic.
For instance, the Department of Agriculture, Environment, and Rural Affairs
(DAERA) in the U.K. introduced measures in March 2020 to support the resumption
of bovine Tuberculosis (TB) testing activities that were disrupted during the
COVID-19 pandemic. These measures encouraged herd keepers to complete overdue
TB tests that had been delayed due to the pandemic. Similarly, the Michigan
Department of Agriculture and Rural Development (MDARD) in the U.S. ensured
that activities under the Bovine Tuberculosis Eradication Program, such as TB
testing, continued during the pandemic while adhering to precautions to prevent
the spread of the disease.
Several driving factors continue to fuel the market
for bovine TB diagnosis, including government-led bovine TB eradication and
surveillance initiatives, research and development efforts by major companies,
a return to normalcy post-pandemic, and the expansion of test types and service
offerings. For instance, in June 2019, the World Organization for Animal Health
(OIE) approved the Enferplex Bovine TB Antibody test, manufactured by Enfer
Group in Ireland. This test kit aids in detecting antibodies to M. bovis in
cattle serum samples and is recommended by OIE for serological infection
diagnosis and management. Enfer Group also expanded its distribution channel by
partnering with Sure Farm Ltd in the U.K., contributing to the market's growth
during the forecast period.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Bovine Tuberculosis Diagnosis Market.”
The Global Bovine Tuberculosis Diagnosis Market is
segmented into tests, regional distribution, and company.
Based on its tests, the molecular
diagnostic tests was the dominated in the market, though
serological tests are also gaining traction and are expected to play an
increasingly prominent role in the future. Molecular diagnostic tests, such as
Polymerase Chain Reaction (PCR) and next-generation sequencing (NGS), have
become essential due to their high sensitivity and specificity, which allow for
the early and accurate detection of Mycobacterium bovis, the bacteria
responsible for bTB. One of the key advantages of molecular diagnostic
techniques is their ability to detect the presence of the pathogen's DNA
directly, even at low bacterial loads, and before clinical signs of the disease
are visible. PCR tests, for example, can amplify DNA from M. bovis, enabling
detection in samples from animals that are not yet showing symptoms of bTB.
This early detection is crucial for preventing the spread of the disease within
herds, as infected animals can be isolated or culled before they have a chance
to transmit the bacteria to others. NGS can provide a more
detailed analysis of the bacterial strain, which is useful for understanding
the epidemiology of the disease and tracking its transmission.
As molecular
diagnostic technologies have advanced, the cost of PCR and NGS has decreased,
and the techniques have become more accessible. This has led to their increased
adoption in veterinary practices worldwide. While the initial investment in
equipment and infrastructure required for molecular diagnostics is higher than
for traditional methods, the long-term benefits—such as faster results, better
accuracy, and the ability to detect infection at earlier stages—are driving the
growth of molecular diagnostic tests in the bTB diagnosis market. Their rapid
response times make them especially valuable in regions with high cattle
populations, where outbreaks can spread quickly and need to be contained as
soon as possible.
Based on region, North America
emerges as the second dominating region in the market. This dominance can be
attributed to various factors, including robust healthcare infrastructure,
advanced diagnostic technologies, significant investments in veterinary
research, and strong government policies for disease control. The United States
and Canada have well-established veterinary diagnostic sectors that prioritize
animal health, making them leaders in bTB diagnostics. Both countries have
large cattle populations, and bTB remains a key concern due to the economic and
public health risks associated with the disease. In the U.S., the USDA (United
States Department of Agriculture) has stringent testing and surveillance
programs to control the spread of bTB in cattle, including regulatory measures
that require regular testing of cattle, particularly in regions where the
disease has been detected. The importance of early detection and rapid response
in preventing bTB outbreaks drives the demand for advanced diagnostic tools,
including molecular diagnostics, serological tests, and traditional methods
like the tuberculin skin test and interferon-gamma assays.
North
America benefits from a highly developed veterinary diagnostic infrastructure
and access to cutting-edge technologies, such as Polymerase Chain Reaction
(PCR) and next-generation sequencing (NGS), which offer high sensitivity and
specificity in detecting Mycobacterium bovis, the bacteria responsible
for bTB. The adoption of these advanced molecular methods is on the rise in
both the U.S. and Canada, driven by the need for faster, more accurate
detection, and better disease management. This trend is likely to continue as
diagnostic technologies become more affordable and accessible.
Major companies operating in Global Bovine
Tuberculosis Diagnosis Market are:
- IDEXX
Laboratories, Inc.
- PBD
Biotech Ltd
- Zoetis Inc.
- Innovative Diagnostics SAS
- Thermo Fisher Scientific Inc.
- Enfer Group
- AsureQuality Australia Pty Ltd.
- Bio-Rad Laboratories, Inc.
- Bionote USA Inc.
- Neogen Corporation
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The future of
the global bovine tuberculosis (bTB) diagnosis market looks promising, driven
by advancements in diagnostic technologies and increasing demand for early
detection methods. The market is expected to witness substantial growth as
molecular diagnostic techniques, such as PCR and next-generation sequencing
(NGS), become more accessible and cost-effective, enhancing detection accuracy
and speed. The rise of rapid, point-of-care diagnostic tests will
contribute to quicker on-site results, improving disease management and
reducing transportation costs. As global regulatory frameworks become stricter
and surveillance efforts intensify, there will be a growing emphasis on
integrating various diagnostic approaches. The increasing focus on
zoonotic diseases will further propel market growth, particularly in regions
with large agricultural sectors”, said Mr. Karan Chechi,
Research Director of TechSci Research, a research-based management consulting
firm.
“Bovine
Tuberculosis Diagnosis Market - Global Industry Size, Share, Trends,
Opportunity, and Forecast, Segmented By Tests (Molecular Diagnostic Tests,
Serological Tests, Traditional Tests), By Region and Competition, 2020-2030F”, has evaluated
the future growth potential of Global Bovine Tuberculosis Diagnosis Market and
provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Bovine Tuberculosis Diagnosis Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New
York, United States- 10170
Tel: +1-332-258-6602
Email: sales@techsciresearch.com
Website: www.techsciresearch.com